Status:

COMPLETED

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Conditions:

Attention-Deficit/Hyperactivity Disorder

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Eligibility Criteria

Inclusion

  • Have voluntarily signed an informed consent form.
  • Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with subject.
  • Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG.
  • Female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements.
  • Male subjects must agree to comply with applicable contraceptive requirements.
  • Subject is able to keep required appointments for clinic visits and all tests, including blood draws and examinations.

Exclusion

  • Subject has a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder.
  • Current diagnosis of major depressive disorder, generalized anxiety disorder, PTSD or has a sleep disorder requiring treatment of any kind.
  • Subject has a history of, or ongoing, serious medical problem.
  • Subject has a history of significant allergic reaction to any drug.
  • Subject is planning to begin any type of behavioral or psychotherapy for treatment of ADHD.
  • Subject requires ongoing treatment with any psychiatric medication.

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT00640185

Start Date

March 1 2008

End Date

August 1 2008

Last Update

January 18 2013

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Site Reference ID/Investigator# 7546

Lafayette, California, United States, 94549

2

Site Reference ID/Investigator# 7551

Jacksonville, Florida, United States, 32216

3

Site Reference ID/Investigator# 7553

Orlando, Florida, United States, 32806

4

Site Reference ID/Investigator# 7545

Overland Park, Kansas, United States, 66212